Showing 5081-5090 of 10633 results for "".
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Medical Entrepreneur Symposium Adds Breakout Sessionhttps://practicaldermatology.com/news/20121024-medical_entrepreneur_symposium_adds_breakout_session/2459693/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers, and executives in healthcare, has added a breakout session for physician entrepreneurs wanting to take great business ideas or medical devices to market. Dr. Arlen Meyers will be the course direct
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- Sciton Expanding in Canadahttps://practicaldermatology.com/news/20120229-sciton_expanding_in_canada/2459860/Sciton, Inc., is establishing a direct presence in Canada. Noting a very strong and loyal customer base within Canada, the company says it views the Canadian market as an integral part of its corporate growth strategy. Sciton will expand its marketing, sales, clinical education and service offerings
- ARTAS System Receives Canadian Medical Device License to Treat Hair Losshttps://practicaldermatology.com/news/20120229-artas_system_receives_canadian_medical_device_license_to_treat_hair_loss/2459861/Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS™ System has received a Canadian Medical Device License and can now be marketed and sold within Canada. The physician controlled ARTAS™ System allows them to quickly identify and harvest
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.